Loading
NBEA (Neurobeachin) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma, Breast cancer, Colorectal cancer and 5 more.
Binds to type II regulatory subunits of protein kinase A and anchors/targets them to the membrane. May anchor the kinase to cytoskeletal and/or organelle-associated proteins.
Open Targets scores its association with cancer at 0.64 (direct and indirect evidence; datatypes literature 0.16, animal model 0.41, genetic association 0.62, somatic mutation 0.74). IntOGen calls it a driver in 14 cohorts (6 activating, 8 loss-of-function), covering Invasive Breast Carcinoma, Cervical Adenocarcinoma, Colon Adenocarcinoma, Colorectal Adenocarcinoma, Oesophageal Adenocarcinoma, Hepatocellular Carcinoma and others.
In plain words · NBEA (Neurobeachin) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma, Breast cancer, Colorectal cancer and 5 more.
NBEA (Neurobeachin) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma, Breast cancer, Colorectal cancer and 5 more.
Binds to type II regulatory subunits of protein kinase A and anchors/targets them to the membrane. May anchor the kinase to cytoskeletal and/or organelle-associated proteins.
No product in this corpus aims at NBEA yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
First described 1998. Earliest sequence paper UniProt cites for the protein: Tchernev V.T. et al, 1998, "Identification of LYST2, a brain-specific member of the Chediak-Higashi syndrome gene family". Source.
Sources: HGNC HGNC:7648 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q8NFP9 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000172915 (association with cancer (MONDO_0004992) 0.64; per-cancer scores at or above 0.5: ovarian cancer 0.51 (GraphQL API, CC0)); IntOGen NBEA (driver in 14 cohorts (Act 6, LoF 8); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Binds to type II regulatory subunits of protein kinase A and anchors/targets them to the membrane. May anchor the kinase to cytoskeletal and/or organelle-associated proteins. Location: Cytoplasm; Membrane (UniProt). Locus 13q13.3 (HGNC).
Query for this target: (TITLE:"NBEA" OR ABSTRACT:"NBEA" OR TITLE:"neurobeachin" OR ABSTRACT:"neurobeachin" OR TITLE:"Neurobeachin" OR ABSTRACT:"Neurobeachin" OR TITLE:"KIAA1544" OR ABSTRACT:"KIAA1544" OR TITLE:"BCL8B" OR ABSTRACT:"BCL8B" OR TITLE:"FLJ10197" OR ABSTRACT:"FLJ10197") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about NBEA, not a curated reading list.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, Hepatocellular carcinoma, IntOGen.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, IntOGen, Ovarian cancer.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, IntOGen, Gastric & gastro-oesophageal junction cancer.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, IntOGen, Breast cancer (all types).
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, IntOGen, Gastric & gastro-oesophageal junction cancer.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, IntOGen, Open Targets Platform.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, Cervical cancer, IntOGen.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, IntOGen, Ovarian cancer.